Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints. J of Skin [Internet]. 2021 Sep. 13 [cited 2025 May 18];5(5):524-9. Available from: https://skin.dermsquared.com/skin/article/view/1309